Voyager Therapeutics, Inc. (VYGR) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 2.59
30Y Low2.6·High6.7
P/FCF
N/A
—
5yr avg: 5.04
30Y Low2.3·High12.2
P/B Ratio
↑
1.19
↓-33% vs avg
5yr avg: 1.78
30Y Low0.5·High6.5
ROE
↑
-48.3%
↑-141% vs avg
5yr avg: -20.1%
30Y Low-98%·High90%
Debt/EBITDA
N/A
—
5yr avg: 0.16
30Y Low0.2·High1.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VYGR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Voyager Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $234M | $231M | $327M | $376M | $234M | $102M | $267M | $501M | $301M | $445M | $322M |
| Enterprise Value | $205M | $202M | $299M | $328M | $158M | $29M | $210M | $449M | $255M | $413M | $286M |
| P/E Ratio → | -1.94 | — | — | 2.84 | — | — | 7.30 | — | — | — | — |
| P/S Ratio | 5.79 | 5.71 | 4.09 | 1.50 | 5.72 | 2.73 | 1.56 | 4.80 | 39.56 | 43.90 | 22.67 |
| P/B Ratio | 1.19 | 1.18 | 1.09 | 1.59 | 3.96 | 1.07 | 1.73 | 5.03 | 6.49 | 3.32 | 2.37 |
| P/FCF | — | — | — | 5.04 | — | — | — | 12.23 | — | — | — |
| P/OCF | — | — | — | 4.83 | — | — | — | 10.29 | — | — | — |
P/E links to full P/E history page with 30-year chart
VYGR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.00 | 3.74 | 1.31 | 3.87 | 0.77 | 1.23 | 4.30 | 33.41 | 40.79 | 20.09 |
| EV / EBITDA | — | — | — | 2.59 | — | — | 6.74 | — | — | — | — |
| EV / EBIT | — | — | — | 2.69 | — | — | 7.68 | — | — | — | — |
| EV / FCF | — | — | — | 4.39 | — | — | — | 10.96 | — | — | — |
VYGR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Voyager Therapeutics, Inc. earns an operating margin of -326.6%. Operating margins have compressed from 48.8% to -326.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -48.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 63.1% | -36.3% | -97.2% | 36.4% | -14.7% | -751.9% | -514.3% | -197.1% |
| Operating Margin | -326.6% | -326.6% | -104.1% | 48.8% | -124.3% | -196.8% | 16.0% | -49.5% | -1195.6% | -709.1% | -290.4% |
| Net Profit Margin | -296.5% | -296.5% | -81.3% | 52.9% | -113.4% | -190.3% | 21.5% | -41.8% | -1158.8% | -697.6% | -282.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -48.3% | -48.3% | -24.3% | 89.6% | -60.2% | -57.1% | 28.9% | -59.7% | -97.8% | -52.4% | -26.4% |
| ROA | -37.1% | -37.1% | -17.5% | 51.8% | -26.3% | -31.3% | 11.9% | -16.4% | -48.8% | -37.8% | -19.2% |
| ROIC | -45.0% | -45.0% | -27.2% | 107.0% | -1528.8% | -92.6% | 28.3% | -164.1% | -133.8% | -53.4% | -26.1% |
| ROCE | -46.3% | -46.3% | -26.4% | 65.3% | -44.3% | -39.0% | 10.7% | -24.4% | -58.0% | -41.7% | -21.7% |
VYGR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $65M exceeds total debt of $36M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | 0.15 | 0.09 | 0.39 | 0.46 | 0.31 | 0.34 | — | — | — |
| Debt / EBITDA | — | — | — | 0.16 | — | — | 1.53 | — | — | — | — |
| Net Debt / Equity | — | -0.15 | -0.09 | -0.21 | -1.28 | -0.77 | -0.37 | -0.52 | -1.01 | -0.24 | -0.27 |
| Net Debt / EBITDA | — | — | — | -0.38 | — | — | -1.82 | — | — | — | — |
| Debt / FCF | — | — | — | -0.65 | — | — | — | -1.27 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -42.31 |
Net cash position: cash ($65M) exceeds total debt ($36M)
VYGR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Voyager Therapeutics, Inc.'s current ratio of 7.64x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.96x to 7.64x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.64 | 7.64 | 5.56 | 4.96 | 1.72 | 2.68 | 7.39 | 4.01 | 5.13 | 10.81 | 12.95 |
| Quick Ratio | 7.64 | 7.64 | 5.56 | 4.96 | 1.72 | 2.68 | 7.39 | 3.98 | 4.97 | 10.69 | 12.84 |
| Cash Ratio | 7.40 | 7.40 | 5.36 | 3.58 | 1.64 | 2.60 | 6.77 | 3.70 | 4.92 | 10.63 | 12.64 |
| Asset Turnover | — | 0.16 | 0.20 | 0.71 | 0.26 | 0.19 | 0.65 | 0.29 | 0.04 | 0.05 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | 54.38 | 12.69 | 33.65 | 27.72 |
| Days Sales Outstanding | — | 15.92 | 20.49 | 123.30 | 5.70 | 7.30 | 17.09 | 65.38 | 9.63 | — | 59.11 |
VYGR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Voyager Therapeutics, Inc. returns 0.2% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 35.2% | — | — | 13.7% | — | — | — | — |
| FCF Yield | — | — | — | 19.8% | — | — | — | 8.2% | — | — | — |
| Buyback Yield | 0.2% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.2% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% |
| Shares Outstanding | — | $59M | $58M | $45M | $38M | $38M | $37M | $36M | $32M | $27M | $25M |
Peer Comparison
Compare VYGR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VYGRYou | $234M | -1.9 | — | — | — | -326.6% | -48.3% | -45.0% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 ADVM | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 RGNX | $527M | -2.3 | — | — | 59.7% | -280.0% | -79.5% | -53.8% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See VYGR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VYGR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VYGR vs SRPT
Side-by-side business, growth, and profitability comparison vs Sarepta Therapeutics, Inc..
Start ComparisonVYGR — Frequently Asked Questions
Quick answers to the most common questions about buying VYGR stock.
What is Voyager Therapeutics, Inc.'s P/E ratio?
Voyager Therapeutics, Inc.'s current P/E ratio is -1.9x. The historical average is 5.1x.
What is Voyager Therapeutics, Inc.'s ROE?
Voyager Therapeutics, Inc.'s return on equity (ROE) is -48.3%. The historical average is -31.1%.
Is VYGR stock overvalued?
Based on historical data, Voyager Therapeutics, Inc. is trading at a P/E of -1.9x. Compare with industry peers and growth rates for a complete picture.
What are Voyager Therapeutics, Inc.'s profit margins?
Voyager Therapeutics, Inc. has -326.6% operating margin.